bryostatin

(redirected from Bryostatins)
Also found in: Wikipedia.

bryostatin

Any of a group of 20 different macrolide lactones isolated from a species of bryozoans (moss animals), a phylum of aquatic invertebrates (Bugula neritina), which upregulate protein kinase C (PKC) activity in the short term, and downregulate PKC with prolonged exposure. Bryostatin I inhibits cell growth and angiogenesis, drives cell differentiation and apoptosis and has immunomodulatory activity. While it showed promise as a memory enhancer and in cancer management, it failed as a monotherapy in phase-II clinical trials.
 
Adverse effects
Myalgia.
Mentioned in ?
References in periodicals archive ?
2004), whereas bryostatins, anticancer agents first isolated from the bryozoan Bugula neritina, require the microbial symbiont Endobugula sertula for their synthesis (Davidson et al.
Evidence for the biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula neritina.
Spencer 3:00 STUDIES OF Fe(III) COMPLEXING WITH BRYOSTATINS, ANALOGS AND MARINE NATURAL PRODUCTS: MAKING BETTER PHAMECEUTICAL AGENTS, Jessica Thomas* and Thomas J.
Eduardo MuSoz, lead inventor and Chief Scientific Officer of VivaCell Biotechnology EspaSa states that: "From our experiments using a specific and suitable model for HIV-1 reactivation, we determined which combinations of bryostatins and HDACs inhibitors synergise to antagonise HIV-1 latency.
This invention relates to pharmaceutical compositions, particularly pharmaceutical compositions comprising a bryostatin-1, other bryostatins and substituted derivatives of bryostatins for use in treating inflammation, and for use in combating arteriosclerosis, diseases of the cardiovascular system and the central nervous system, prior to and following organ transplantation, and ischemia [United States Patent Pending].
Aphios Corporation is developing improved nanotechnology formulations of bryostatin 1 [US and International Patents], which is more water-soluble than the potent anticancer drug paclitaxel with its known formulation and manufacturing difficulties.
35] is examined by FT-ICR because its structure may represent the bryophan ring, the central structural feature in all bryostatins.
35] ring could serve as a precursor for the bryostatins extracted from Bugula neritina.
The technology can also be utilized to manufacture natural pharmaceuticals such as taxols, bryostatins and camptothecins.
The study demonstrated that bryostatin was the most potent compound showing statistically significant activity at the nanomolar concentration.
We focused on bryostatin and ET743, two pharmaceutical agents that have entered clinical trials but are extraordinarily expensive (> $5 million per gram for high purity form).